Naphak Modhiran

Dr. Naphak Modhiran

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
NMNaphak Modhiran
Naphak Modhiran
DWDaniel Watterson
Daniel Watterson
DMDavid A. Muller
David A. Muller
APAdele K. Panetta
Adele K. Panetta
DSDavid P. Sester
David P. Sester
PYPaul Young
Paul Young
Dengue virus NS1 protein induces inflammatory responses via TLR4 and disrupts endothelial cell monolayer integrity.

8 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAlberto A. Amarilla
Alberto A. Amarilla
JSJulian D. J. Sng
Julian D. J. Sng
Rhys ParryRhys Parry
Rhys Parry
JDJoshua M. Deerain
Joshua M. Deerain
JPJames R. Potter
James R. Potter
AKAlexander Khromykh
Alexander Khromykh
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that despite the large size of the viral RNA genome (~30 kb), infectious full-length cDNA is readily assembled in vitro by a circular polymerase extension reaction (CPER) methodology without the need for technically demanding intermediate steps. Overlapping cDNA fragments are generated from viral RNA and assembled together with a linker fragment containing CMV promoter into a circular full-length viral cDNA in a single reaction. Transfection of the circular cDNA into mammalian cells results in the recovery of infectious SARS-CoV-2 virus that exhibits properties comparable to the parental virus in vitro and in vivo. CPER is also used to generate insect-specific Casuarina virus with ~20 kb genome and the human pathogens Ross River virus (Alphavirus) and Norovirus (Calicivirus), with the latter from a clinical sample. Additionally, reporter and mutant viruses are generated and employed to study virus replication and virus-receptor interactions.

15 March 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SUSukathida Ubol
Sukathida Ubol
WPWeerawat Phuklia
Weerawat Phuklia
SKSiripen Kalayanarooj
Siripen Kalayanarooj
NMNaphak Modhiran
Naphak Modhiran
We have found that dengue virus (DENV) not only uses preexisting enhancing antibodies to promote its entry into Fc receptor-bearing cells but also ex

1 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKevin J. Selva
Kevin J. Selva
Carolien Emma van de SandtCarolien Emma van de Sandt
Carolien Emma van de Sandt
MLMelissa M. Lemke
Melissa M. Lemke
CLChristina Y. Lee
Christina Y. Lee
SSSuzanne K. Shoffner
Suzanne K. Shoffner
ACAmy W. Chung
Amy W. Chung
The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to understand such divergent clinical outcomes. Here we show analysis of coronavirus antibody responses of pre-pandemic healthy children (n = 89), adults (n = 98), elderly (n = 57), and COVID-19 patients (n = 50) by systems serology. Moderate levels of cross-reactive, but non-neutralizing, SARS-CoV-2 antibodies are detected in pre-pandemic healthy individuals. SARS-CoV-2 antigen-specific Fcγ receptor binding accurately distinguishes COVID-19 patients from healthy individuals, suggesting that SARS-CoV-2 infection induces qualitative changes to antibody Fc, enhancing Fcγ receptor engagement. Higher cross-reactive SARS-CoV-2 IgA and IgG are observed in healthy elderly, while healthy children display elevated SARS-CoV-2 IgM, suggesting that children have fewer hCoV exposures, resulting in less-experienced but more polyreactive humoral immunity. Age-dependent analysis of COVID-19 patients, confirms elevated class-switched antibodies in elderly, while children have stronger Fc responses which we demonstrate are functionally different. These insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.

1 June 2016 in Antiviral Research
Verified
Journal Article
Closed access
DWDaniel Watterson
Daniel Watterson
NMNaphak Modhiran
Naphak Modhiran
PYPaul Young
Paul Young

8 January 2021 in Science
Verified
Journal Article
Closed access
PDF file
NMNaphak Modhiran
Naphak Modhiran
HSHao Song
Hao Song
LLLidong Liu
Lidong Liu
CBCheryl Bletchly
Cheryl Bletchly
LBLou Brillault
Lou Brillault
DWDaniel Watterson
Daniel Watterson
Two antibodies against flaviviruses: Flaviviruses are a group of RNA viruses that include the human pathogens dengue virus, Zika virus, and West Nile virus. The envelope protein (E) on the virus surface has been the target of vaccine development, but problems have arisen with antibodies against E, leading to enhanced infection. Now, Modhiran et al. and Biering et al. describe two different antibodies that bind to the flavivirus NS1 protein and prevent it from disrupting epithelial cells, which is associated with severe disease. Both antibodies cross-react with multiple flavivirus NS1 proteins. The antibodies reduce viremia and increase survival in mouse models of flavivirus disease. Both papers include structures of NS1 bound to an antibody, which give insight into the protective mechanism. Science , this issue p. 190 , p. 194